Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Cancer Vaccines01:30

Cancer Vaccines

926
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
926
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Activation-induced SLC7A1 expression enhances T cell sensitivity to cGAMP-mediated STING signaling.

Cell reports·2026
Same author

Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy.

Materials today. Bio·2026
Same author

PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.

Nature communications·2026
Same author

Degrading TBK1 to disarm VHL-deficient renal cancer.

Cell chemical biology·2026
Same author

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.

Cancer cell·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Targeting STING to generate therapeutic anti-tumor immunity.

Caroline G Fahey1, Anthony F Cordova2, Patrick C Gedeon3

  • 1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Harvard University, Cambridge, MA, USA.

Cancer Cell
|December 25, 2025
PubMed
Summary

The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is crucial for cancer immunity. Understanding its complex roles in the tumor microenvironment is key to developing effective STING agonist therapies.

Keywords:
STINGanti-tumor immunitycGASinnate immunityinterferontumor microenvironment

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K

Related Experiment Videos

Last Updated: Jan 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • The cGAS-STING pathway links cytosolic DNA detection to type I interferon production, critical in cancer immunity.
  • Clinical translation of STING agonists faces challenges due to model system limitations and the pathway's complexity.

Purpose of the Study:

  • To review the multifaceted roles of STING activation within the tumor microenvironment (TME).
  • To discuss how current insights can guide the development of novel STING-based cancer immunotherapies.

Main Methods:

  • Literature review of STING pathway function in cancer.
  • Analysis of STING's context- and cell-type-dependent effects in the TME.
  • Evaluation of type I interferon and interferon-independent STING signaling in tumor immunity.

Main Results:

  • STING activation yields diverse outcomes in tumor cells, myeloid cells, and T cells within the TME.
  • Type I interferon induction by STING can be both pro- and anti-tumorigenic.
  • STING signaling possesses emerging interferon-independent functions impacting tumor biology.

Conclusions:

  • A comprehensive understanding of STING's complex TME interactions is essential.
  • Next-generation STING therapies should leverage these insights to enhance anti-tumor immunity and durability.